hCG as Adjunct Therapy in TRT

Understand

Overview

Human chorionic gonadotropin (hCG) is a hormone that mimics luteinizing hormone (LH), sometimes added to testosterone replacement therapy (TRT) specifically to counteract one of its less obvious but significant side effects — testicular atrophy and loss of fertility. Exogenous testosterone alone, through negative feedback, suppresses LH and FSH secretion from the pituitary, which over time leads to shrinking testes and a halt in sperm production. This problem is often underappreciated by men starting TRT — focused on improved mood, energy, or libido, they rarely realize that the same hormone improving their quality of life is simultaneously shutting down their own testosterone and sperm production in the testes.

A 2005 study by Coviello and colleagues showed that low doses of hCG, added to standard testosterone therapy, are able to maintain intratesticular testosterone concentration — essential for spermatogenesis — at a level close to normal, even though serum testosterone is being maintained by the externally administered hormone rather than the body's own production. Despite being conducted on a small group of healthy men rather than long-term TRT patients, this study remains the most frequently cited mechanistic evidence supporting the idea of adding hCG to testosterone therapy in the first place.

A direct comparison of hCG against testosterone alone comes from a 2012 study by Yang and colleagues involving 242 men with hypogonadotropic hypogonadism — a condition in which the hypothalamic-pituitary-testicular axis is impaired, mechanistically similar to the situation of a man on TRT whose own axis is suppressed by external testosterone. In the group treated with hCG alone, testicular volume increased in 50% of patients, on average from 2.0±1.1 to 6.8±3.2 mL, while in the group combining hCG with hMG (menopausal gonadotropin with both LH- and FSH-like activity), 75.7% of patients responded, with volume increasing to 8.8±3.9 mL. Crucially for men considering TRT, in this same study the group treated with testosterone alone — without any gonadotropin — showed no statistically significant increase in testicular volume. This is one of the few examples of direct clinical data confirming what the mechanism itself implies: exogenous testosterone alone does not rebuild or maintain testicular size the way hCG does.

The most extensive, though still indirect, data on the effectiveness of gonadotropin therapy comes from a 2025 meta-analysis by Muir and colleagues, covering 41 studies and 1,673 patients with hypogonadotropic hypogonadism treated with gonadotropins to restore fertility — again, not men on classic TRT, but a population with an analogous mechanism of suppressed hormonal axis function. After a median of 18 months of treatment, mean sperm concentration was 11.6 million/mL (95% CI 8.4-14.9), and the proportion of patients reaching successive sperm-count thresholds was: 78% for >0 million/mL, 55% for >1 million/mL, 36% for >5 million/mL, 24% for >10 million/mL, and 15% for >20 million/mL — a distribution showing that individual treatment response varies enormously, and not every patient reaches parameters considered fully normal. Combined hCG+FSH therapy significantly outperformed hCG alone specifically on sperm output, while the increase in testosterone and testicular volume did not differ significantly between the hCG-alone group and the hCG+FSH group — suggesting that hCG alone drives most of the testosterone and testicular-volume benefit, while adding FSH mainly boosts sperm count specifically.

A practically important observation comes from a 2021 study by Shah and colleagues, in which hCG was gradually escalated up to 2000 units three times a week or 5000 units twice a week (combined with hMG), titrated to reach a testosterone level of at least 3.5 ng/mL. Final mean testicular volume was 8.9±5.5 mL, 86% of patients reached the target testosterone level, and 70% achieved spermatogenesis. However, the most important finding of this study for men who have already been on testosterone alone is a different one: patients with prior exposure to testosterone replacement therapy achieved significantly lower peak sperm counts than gonadotropin-treatment-naive men (median 0.05 vs 9 million/mL; p=0.004). This is a practical, if uncomfortable, takeaway for men currently on testosterone alone without hCG who only plan fertility for the future — the longer the exposure to TRT alone without protecting the hormonal axis, the potentially harder the later return to full spermatogenesis may be, which argues for considering hCG earlier rather than deferring that decision.

Who can this actually help? Men starting TRT who plan to preserve fertility in the future or want to avoid noticeable testicular atrophy — hCG is one of the few strategies allowing testosterone therapy to be combined with preserved testicular function. It's worth noting that most of the numerical data cited above comes from studies of men with hypogonadotropic hypogonadism treated with gonadotropins to restore fertility, not strictly from a population of men on typical TRT with added hCG — the mechanism of suppression of the hypothalamic-pituitary-testicular axis is close enough, however, that this data is widely regarded as mechanistically relevant and clinically useful when planning a TRT+hCG protocol, even though these studies weren't conducted one-to-one on this exact population. The decision to add hCG should be made together with the endocrinologist managing the therapy, not independently, and should take into account the individual goal — whether the priority is solely preserving testicular volume, or actively planning for children in the near future.